Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Assets (2019 - 2025)

BioNexus Gene Lab's Return on Assets history spans 7 years, with the latest figure at 0.27% for Q3 2025.

  • For Q3 2025, Return on Assets fell 18.0% year-over-year to 0.27%; the TTM value through Sep 2025 reached 0.27%, down 18.0%, while the annual FY2024 figure was 0.15%, 11.0% up from the prior year.
  • Return on Assets for Q3 2025 was 0.27% at BioNexus Gene Lab, up from 0.33% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.08% in Q4 2021 and bottomed at 0.33% in Q2 2025.
  • The 5-year median for Return on Assets is 0.06% (2023), against an average of 0.1%.
  • The largest annual shift saw Return on Assets plummeted -108bps in 2021 before it grew 22bps in 2024.
  • A 5-year view of Return on Assets shows it stood at 0.08% in 2021, then plummeted by -138bps to 0.03% in 2022, then plummeted by -644bps to 0.23% in 2023, then rose by 30bps to 0.16% in 2024, then tumbled by -69bps to 0.27% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Return on Assets are 0.27% (Q3 2025), 0.33% (Q2 2025), and 0.23% (Q1 2025).